There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axovant Sciences (NYSE: AXON), Axsome Therapeutics Inc (NASDAQ: AXSM) and Pieris Pharmaceuticals (NASDAQ: PIRS) with bullish sentiments.
Axovant Sciences (NYSE: AXON)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Axovant Sciences (NYSE: AXON) today and set a price target of $11. The company’s shares closed yesterday at $4.55, close to its 52-week low of $1.02.
Fein said:
“We believe the licensing agreement with the exclusive worldwide rights to develop and commercialize AXO- Lenti-PD marks the rebirth of Axovant as a pioneering GT company in the CNS space. As a novel approach, GT has shown promising potentials in Parkinson’s disease (PD), and we believe lentiviral vectors may be particularly suited for PD as compared to AAV-mediated gene delivery methods (discussed below). With the recent management restructuring to include industry veterans in the GT space, the leading lentiviral therapy technologies from the strong in-house expertise in the CNS space, Axovant has undertaken a bold and measured transformation that sets the tone for future optionality beyond PD, and should engage new investors who are interested in the intersection between GT and CNS spaces, in our view.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 8.3% and a 53.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Axovant Sciences has an analyst consensus of Hold, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
Axsome Therapeutics Inc (NASDAQ: AXSM)
In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with a Buy rating on Axsome Therapeutics Inc (NASDAQ: AXSM) and a price target of $10. The company’s shares closed yesterday at $3.60.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.9% and a 40.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Axsome Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $16.
Pieris Pharmaceuticals (NASDAQ: PIRS)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Pieris Pharmaceuticals (NASDAQ: PIRS), with a price target of $12. The company’s shares closed yesterday at $5.87.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -10.3% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Pieris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
